Zabel Robert, Kullmann Maximilian, Kalayda Ganna V, Jaehde Ulrich, Weber Günther
Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V, Dortmund, Germany.
Electrophoresis. 2015 Feb;36(4):509-17. doi: 10.1002/elps.201400467. Epub 2015 Jan 28.
Pt-based anticancer drugs, such as cisplatin, are known to undergo several (bio-)chemical transformation steps after administration. Hydrolysis and adduct formation with small nucleophiles and larger proteins are their most relevant reactions on the way to the final reaction site (DNA), but there are still many open questions regarding the identity and pharmacological relevance of various proposed adducts and intermediates. Furthermore, the role of buffer components or additives, which are inevitably added to samples during any type of analytical measurement, has been frequently neglected in previous studies. Here, we report on adduct formation reactions of the fluorescent cisplatin analogue carboxyfluorescein diacetate platinum (CFDA-Pt) in commonly used buffers and cell culture medium. Our results indicate that chelation reactions with noninnocent buffers (e.g., Tris) and components of the cell culture/cell lysis medium must be taken into account when interpreting results. Adduct formation kinetics was followed up to 60 h at nanomolar concentrations of CFDA-Pt by using CE-LIF. CE-MS enabled the online identification of such unexpected adducts down to the nanomolar concentration range. By using an optimized sample preparation strategy, unwanted adducts can be avoided and several fluorescent adducts of CFDA-Pt are detectable in sensitive and cisplatin-resistant cancer cell lines. By processing samples rapidly after incubation, we could even identify the initial, but transient, Pt species in the cells as deacetylated CFDA-Pt with unaltered complexing environment at Pt. Overall, the proposed procedure enables a very sensitive and accurate analysis of low molecular mass Pt species in cancer cells, involving a fast CE-LIF detection within 5 min.
基于铂的抗癌药物,如顺铂,在给药后会经历几个(生物)化学转化步骤。与小分子亲核试剂和较大蛋白质的水解及加合物形成是它们在到达最终反应位点(DNA)途中最相关的反应,但关于各种提出的加合物和中间体的身份及药理相关性仍有许多未解决的问题。此外,在任何类型的分析测量过程中不可避免地添加到样品中的缓冲液成分或添加剂的作用,在先前的研究中经常被忽视。在此,我们报告了荧光顺铂类似物羧基荧光素二乙酸铂(CFDA-Pt)在常用缓冲液和细胞培养基中的加合物形成反应。我们的结果表明,在解释结果时必须考虑与非惰性缓冲液(如Tris)以及细胞培养/细胞裂解培养基成分的螯合反应。通过使用CE-LIF,在纳摩尔浓度的CFDA-Pt下跟踪加合物形成动力学长达60小时。CE-MS能够在线鉴定低至纳摩尔浓度范围的此类意外加合物。通过使用优化的样品制备策略,可以避免不需要的加合物,并且在敏感和顺铂耐药癌细胞系中可检测到几种CFDA-Pt的荧光加合物。通过在孵育后快速处理样品,我们甚至可以将细胞中最初但短暂的铂物种鉴定为脱乙酰化的CFDA-Pt,其铂的络合环境未改变。总体而言,所提出的程序能够对癌细胞中的低分子量铂物种进行非常灵敏和准确的分析,包括在5分钟内进行快速的CE-LIF检测。